19. Prophylaxis in Hemophilia a Patients with Inhibitors

  1. Emérito-Carlos Rodríguez-Merchán MD, PHD2,3 and
  2. Leonard A. Valentino MD4
  1. Leonard A. Valentino MD4 and
  2. Guy Young MD1

Published Online: 12 MAY 2011

DOI: 10.1002/9781119979401.ch19

Current and Future Issues in Hemophilia Care

Current and Future Issues in Hemophilia Care

How to Cite

Valentino, L. A. and Young, G. (2011) Prophylaxis in Hemophilia a Patients with Inhibitors, in Current and Future Issues in Hemophilia Care (eds E.-C. Rodríguez-Merchán and L. A. Valentino), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781119979401.ch19

Editor Information

  1. 2

    Department of Orthopedic Surgery and Hemophilia Unit, La Paz University Hospital, Spain

  2. 3

    School of Medicine, Autonomous University, Madrid, Spain

  3. 4

    Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA

Author Information

  1. 1

    UCLA Health System, Los Angeles, CA, USA

  2. 4

    Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA

Publication History

  1. Published Online: 12 MAY 2011
  2. Published Print: 13 MAY 2011

ISBN Information

Print ISBN: 9780470670576

Online ISBN: 9781119979401

SEARCH

Keywords:

  • activated prothrombin complex concentrate;
  • bypassing therapy;
  • factor VIII;
  • hemophilia;
  • inhibitor;
  • prophylaxis;
  • recombinant activated factor VII

Summary

Prophylaxis with bypassing therapy is increasingly being used to reduce the high risk for joint disease and severe hemorrhage in patients with severe hemophilia A and inhibitors to factor VIII. Case reports and the results from two randomized clinical trials indicate that both activated prothrombin complex concentrate and recombinant activated factor VII may be used prophylactically in a variety of clinical settings and, depending on the particular circumstances, may be appropriate for long-term, short-term, and episodic administration.